Description
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (LAPC).
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about TIGeR-PaC Study
Principal Investigator
Co-Investigator(s)
Deepti Behl, MD, Jasdeepa Nagi, M.D., Benjamin Coombs, D.O., Sivakumar Reddy, M.D., Carlin R Hauck, Radiation Oncologist, Charlotte D Kubicky, Radiation Oncologist, Hubert Y Pan, Radiation Oncologist, Anthony T Pu, Radiation Oncologist, Christopher Jones, MD, Vijay Suhag, M.D., Aria Sasaki, M.D., Brian K. Kim, M.D, Henal Patel, M.D.
Funder
RenovoRx